INTERVIEW: The jewel in India's biotech crown
17 November, 2005 by Melissa TrudingerKiran Mazumdar-Shaw spoke with Melissa Trudinger about ways in which India and Australia can work together in biotech.
INTERVIEW: New AusBiotech head stakes her position
17 November, 2005 by Ruth BeranSince she took the top job at AusBiotech on the eve of the BIO conference earlier this year, Anna Lavelle has done a lot of listening. Now she's ready to talk -- about her role and her vision for the organisation.
Hatchtech awarded $2.4m grant
17 November, 2005 by Ruth BeranUnlisted Melbourne biotech Hatchtech has been awarded a AUD$2.4 million AusIndustry Commercial Ready grant to support its head lice treatment R&D program.
Tissue Therapies raises $1.6m, announces SPP
17 November, 2005 by Ruth BeranBrisbane biotech Tissue Therapies (ASX:TIS) has completed a placement to investors, raising AUD$1.6 million before costs.
Premier Bionics division gets Hong Kong order
17 November, 2005 by Helen SchullerMedic Vision, a wholly owned subsidiary of Premier Bionics (ASX:PBI), has received an initial order for its surgical simulation products worth almost $460,000 from a hospital in Hong Kong.
Cryptome to acquire HealthLinx
17 November, 2005 by Helen SchullerMelbourne biopharma Cryptome Pharmaceuticals (ASX:CRP) has entered a non-binding terms sheet to acquire HealthLinx, a privately-held diagnostics specialist with lead candidates targeting ovarian cancer and complications in pregnancy.
Positive performance for Australian life sciences sector
16 November, 2005 by Ruth BeranThe Australian life sciences sector has picked up with small cap stocks seeing positive growth in the last quarter, according to the November edition of PricewaterhouseCoopers' quarterly BioForum report.
Alchemia options worth $2m exercised
16 November, 2005 by Helen SchullerThe Dow Chemical Company has exercised AUD$2 million worth of options in manufacturing partner Alchemia (ASX:ACL).
Deck the Hall -- the Walter and Eliza Hall, that is
16 November, 2005 by Graeme O'NeillAustralia's best-known and most venerable medical research institute, The Walter and Eliza Hall Institute of Medical Research in Parkville, Melbourne, celebrates its 90th anniversary this year. Graeme O'Neill interviewed the Hall's former director, Prof Sir Gustav Nossal, and his successor, Prof Suzanne Cory, about the institute's history and their view of science in Australia today.
Setback for Rockeby in US
14 November, 2005 by Graeme O'NeillAfter a meeting with officials of the US Food and Drug Administration, fungal infection diagnostics specialist Rockeby Biomed (ASX:RBY) has mothballed its attempt to register its point-of-care CanDia5 test for vaginal thrush infection (candidiasis) for use in the US.
Pharmaxis completes capital raising
14 November, 2005 by Helen SchullerPharmaxis (ASX:PXS, Nasdaq:PXSL) has completed its capital raising of AUD$87 million (US$63 million).
BioMD acquires tissue engineering company
14 November, 2005 by Ruth BeranPerth-based medical device and materials company BioMD (ASX:BOD) has paid AUD$650,000 to acquire a 50 per cent equity interest in unlisted tissue engineering company Celxcel.
Keith Williams retires as Proteome director, remains as consultant
11 November, 2005 by Ruth BeranProteome Systems (ASX:PXL) founder Dr Keith Williams is no longer a director of the company he established in 1999, following his decision to withdraw his nomination for re-election at yesterday's AGM.
Mimotopes to team with Genzyme in peptide supply deal
10 November, 2005 by Helen SchullerPharmAust (ASX:PAA) subsidiary Mimotopes will team up with US-based Genzyme Pharmaceuticals in a strategic alliance to provide peptide products and services to both companies' customers globally.
How a code of practice can help manage biotech's conundrum
10 November, 2005 by Michael AldridgeThe new AusBiotech/ASX code of practice for reporting by life science companies, launched last week, is being hailed as an important milestone in the development of the Australian biotech sector. Here, Michael Aldridge, who was on the committee to review the code's first draft, explains why he believes the code is so important to the industry.
